Radiotherapy Market: Growth, Size, Share, and Trends
Radiotherapy Market by Technology (EBRT: LINAC, Stereotactic, Particle; Internal Beam/Brachytherapy, Cobalt-60 Teletherapy), Procedure (IGRT, IMRT, 3D-CRT, LDR, PDR), Cancer (Prostate, Lung, Breast, CRC), End User (Hospital, IRC) - Global Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global radiotherapy market is expected to reach USD 10.68 billion by 2031 from USD 7.98 billion in 2026, at a CAGR of 6.0% during the forecast period. The growth of the radiotherapy market is driven by several factors, including the rising global incidence of cancer, increased spending on healthcare facilities, and growing demand for precision oncology treatments. The rapid adoption of innovative applications such as proton beam therapy, adaptive radiotherapy, stereotactic radiosurgery, and artificial intelligence-based treatment planning is improving the accuracy of tumor treatment while minimizing damage to surrounding tissues.
KEY TAKEAWAYS
-
BY REGIONBy region, the Asia Pacific is projected to witness the highest CAGR of 7.1% during the forecast period.
-
BY OFFERINGBy offering, the systems segment accounted for the largest market share of 55.5% in 2025.
-
BY TECHNOLOGYBy technology, the external beam radiotherapy segment is expected to register the highest CAGR of 5.7% during the forecast period.
-
BY APPLICATIONBy application, the EBRT applications segment dominated the market with a share of 96.0% in 2025.
-
BY PROCEDUREBy procedure, the external beam radiotherapy procedures segment accounted for the largest market share of 96.0% in 2025.
-
BY END USERBy end user, the hospitals segment is projected to grow at the fastest rate of 5.7% from 2026 to 2031.
-
COMPETITIVE LANDSCAPE - KEY PLAYERSSiemens Healthineers AG (Varian Medical Systems, Inc.) (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA Worldwide (Belgium), and ViewRay, Inc. (US) are identified as star players in the radiotherapy market, given their strong global market presence, extensive portfolios, advanced R&D capabilities, and well-established distribution networks across developed and emerging regions.
-
COMPETITIVE LANDSCAPE - OTHER PLAYERSThese companies offer unique products that have started occupying a niche for themselves within the industry. Their business and product superiority is yet to be matched when compared to some other leading start-up firms. Some of the most successful firms in this segment include Brainlab AG (Germany) and BEBIG Medical (Germany).
The growth of the radiotherapy market is driven by several factors, including the rising global incidence of cancer, increased healthcare spending, and a growing demand for precision oncology treatments. The rapid adoption of advanced applications such as proton beam therapy, adaptive radiotherapy, stereotactic radiosurgery, and artificial intelligence-based treatment planning is improving the accuracy of tumor treatment while minimizing damage to surrounding tissues.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Several technological developments and trends are likely to significantly impact the radiotherapy market. Key advancements include sophisticated technologies such as Linear Accelerators (LINACs), proton therapy systems, MRI-guided radiotherapy systems, and stereotactic radiotherapy systems. Additionally, innovations such as artificial intelligence-based treatment-planning solutions, workflow optimization tools, and real-time tumor-tracking systems are expected to shape the market's future. The primary goal of these technological advancements is to enhance the efficacy of radiotherapy procedures. Recently, hypofractionated radiotherapy and image-guided treatment procedures have gained increasing popularity.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Advancements in radiotherapy treatments

-
Increasing use of advanced applications, including adaptive radiotherapy, stereotactic body radiation therapy (SBRT), and MRI-guided radiotherapy
Level
-
Limited access to advanced radiotherapy facilities in low- and middle-income countries
-
Shortage of skilled radiation oncologists, medical physicists, and trained technicians
Level
-
Emerging markets offering significant growth potential for radiotherapy technologies
-
AI-based treatment planning, automated contouring, and adaptive radiotherapy
Level
-
Regulatory complexity and lengthy approval timelines for advanced radiotherapy technologies
-
Managing treatment accuracy for moving tumors through real-time imaging and motion tracking
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Advancements in radiotherapy treatments
Technological advancements in radiotherapy have become a key factor driving the growth of the radiotherapy market. The increasing adoption of advanced treatment technologies, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), MRI-guided linear accelerators (MRI-guided LINACs), adaptive radiotherapy, and AI-based treatment planning software, is significantly improving the precision of radiation doses, the accuracy of tumor targeting, and overall treatment efficiency while minimizing exposure to surrounding healthy tissues. Furthermore, the shift from conventional 2D radiotherapy to real-time image-guided and 3D conformal radiotherapy systems is enhancing clinical outcomes and broadening the applications of radiotherapy across hospitals and cancer care centers. Recent innovations, including AI-powered adaptive CT-LINAC systems, robotic radiosurgery platforms, and real-time motion tracking technologies, are further accelerating the global adoption of advanced radiotherapy solutions.
Restraint: Limited access to advanced radiotherapy facilities in low- and middle-income countries
Limited access to advanced radiotherapy facilities in low- and middle-income countries poses a significant barrier to the radiotherapy market. This issue stems from inadequate healthcare infrastructure, a shortage of skilled oncology professionals, and the high costs associated with advanced radiotherapy systems. Many healthcare facilities in emerging regions struggle to adopt technologies such as proton therapy, MRI-guided radiotherapy, and adaptive radiotherapy due to limited funding and insufficient reimbursement support. Additionally, the uneven distribution of cancer care centers and the delayed installation of advanced treatment systems continue to hinder patient access to precision oncology services. However, emerging trends like compact linear accelerator systems, AI-assisted treatment planning, cloud-based oncology workflows, and mobile radiotherapy solutions are expected to gradually enhance accessibility and operational efficiency in underserved regions.
Opportunity: Emerging markets offering significant growth potential for radiotherapy technologies
Emerging economies offer significant growth opportunities for the radiotherapy market due to the rising prevalence of cancer, improved healthcare infrastructure, and increased investments in oncology care in countries such as China, India, Brazil, and Mexico. Governments in these regions are boosting healthcare spending and enhancing access to advanced cancer treatment technologies. It is projected that government health expenditures will grow by 14% in low-income countries (LICs) and 17% in lower-middle-income countries (LMICs) between 2024 and 2030, which will support the expansion of radiotherapy infrastructure and oncology services. Additionally, the rise of medical tourism, lower treatment costs compared to developed countries, and the increasing adoption of advanced technologies such as AI-enabled radiotherapy, CyberKnife radiosurgery, and proton therapy are creating further significant growth opportunities for the radiotherapy market in emerging economies.
Challenge: Regulatory complexity and lengthy approval timelines for advanced radiotherapy technologies
Regulatory complexity and lengthy approval timelines for advanced radiotherapy technologies pose significant challenges for the radiotherapy market. Advanced systems, such as proton therapy, MRI-guided radiotherapy, adaptive radiotherapy platforms, and AI-based treatment planning software, require extensive clinical validation, safety assessments, and adherence to stringent regulatory standards before they can be commercialized. Variations in regulatory frameworks across different regions further prolong approval timelines and delay the launch of products for market players. Additionally, evolving regulations concerning AI integration, radiation safety, and software interoperability create ongoing operational and compliance challenges for manufacturers developing next-generation radiotherapy solutions.
RADIOTHERAPY MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Provides Varian LINACs and AI-enabled adaptive radiotherapy solutions. | Improves treatment precision and adaptive workflow efficiency. |
|
|
Offers MRI-guided and adaptive radiotherapy systems. | Enables real-time imaging and accurate tumor targeting. |
|
|
Delivers CyberKnife and Radixact radiotherapy platforms. | Supports robotic radiosurgery and motion-tracked treatment delivery. |
|
|
Provides proton therapy and particle therapy solutions. | Minimizes radiation exposure to surrounding healthy tissues. |
|
|
Offers treatment planning and image-guided radiotherapy software. | Enhances workflow efficiency and treatment accuracy. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The stakeholders in the radiotherapy market include manufacturers of radiotherapy systems, providers of software and treatment planning solutions, component suppliers, distributors, hospitals, independent radiotherapy centers, and regulatory authorities. Companies in this market are focused on developing advanced radiotherapy systems, such as linear accelerators (LINACs), MRI-guided radiotherapy systems, particle therapy systems, brachytherapy solutions, and AI-enabled treatment planning platforms to enhance treatment precision and improve clinical outcomes. Suppliers and service providers contribute to the market by delivering consumables, software integration, installation, maintenance, and workflow optimization services. Hospitals and independent radiotherapy centers are the primary end users due to the growing demand for advanced cancer treatment procedures. Regulatory bodies, such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), ensure the safety, efficacy, and approval of innovative radiotherapy technologies. Key companies operating within the radiotherapy ecosystem include Siemens Healthineers AG (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA Worldwide (Belgium), Brainlab AG (Germany), and BEBIG Medical (Germany).
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
RADIOTHERAPY MARKET, BY OFFERING
By offering, the radiotherapy market is divided into systems and software & services. The systems segment is expected to experience significant growth in the coming years due to the increasing popularity of technology-enabled radiotherapy equipment in developing countries and the rising number of manufacturers producing these advanced systems. This segment includes systems, consumables, probes, and applicators used in external beam radiation therapy and brachytherapy. Furthermore, the growing incidence of cancer, the increasing demand for precision radiotherapy, and ongoing advancements in technology are also contributing to the market's expansion.
RADIOTHERAPY MARKET, BY TECHNOLOGY
Based on technology, radiotherapy is segmented into external beam radiotherapy and internal beam radiotherapy/brachytherapy. The external beam radiotherapy segment is anticipated to have the largest market share among other segments during the forecast period, owing to its capability of providing highly accurate and precise tumor targeting without exposing adjacent healthy tissue to any unnecessary radiation. Growth in the adoption of more advanced procedures and increased demand for precision medicine are driving the growth of this segment.
RADIOTHERAPY MARKET, BY APPLICATION
By application, the radiotherapy market is segmented into external beam radiotherapy (EBRT) applications and internal beam radiotherapy (IBRT)/brachytherapy applications. During the forecast period, the external beam radiotherapy (EBRT) applications segment is poised to command the most substantial market share in the radiotherapy market. This dominance is fueled by the increasing adoption and efficacy of EBRT for new cancer types.
RADIOTHERAPY MARKET, BY PROCEDURE
By procedure, the radiotherapy market is segmented into external beam radiotherapy procedures and internal beam radiotherapy/brachytherapy procedures. The external beam radiotherapy procedures segment is estimated to dominate the radiotherapy market during the forecast period, owing to the non-invasive nature of this procedure, high degree of accuracy, low radiation exposure to nearby healthy cells, and increasing adoption of advanced technology-based devices. The rising requirement for personal cancer treatment, high incidence of cancer, and technological innovations are propelling the growth of this segment.
RADIOTHERAPY MARKET, BY END USER
On the basis of end user, the radiotherapy market is classified into hospitals and standalone radiotherapy centers. The hospitals segment will hold the largest share of the worldwide radiotherapy market in the coming years, due to the large volume of patients, availability of advanced radiotherapy equipment, and rising demand for complete cancer treatment facilities in hospitals. The other factors that will support the growth of this segment include the increasing number of hospitals in developing nations, investments in the healthcare infrastructure sector, and availability of trained oncologists.
REGION
Asia Pacific to be fastest-growing region in global radiotherapy market during forecast period
The Asia Pacific region is expected to register the highest CAGR in the radiotherapy market during the forecast period. Asia Pacific comprises China, India, South Korea, Australia, Japan, and the Rest of Asia Pacific. Growth is driven by the increasing prevalence of cancer, an aging population, expanding oncology infrastructure, and growing adoption of advanced radiotherapy equipment such as linear accelerators, image-guided radiation therapy, and proton therapy. Other factors driving the market include increased government spending, increased medical tourism, and collaborations between market vendors.

RADIOTHERAPY MARKET: GROWTH, SIZE, SHARE, AND TRENDS: COMPANY EVALUATION MATRIX
The radiotherapy market is characterized by several established and emerging players operating across the Stars, Emerging Leaders, Pervasive Players, and Participants categories. Companies categorized as Stars, including Siemens Healthineers, Elekta, Accuray, IBA Worldwide, and ViewRay Technologies, hold strong market positions due to their broad product portfolios, advanced radiotherapy technologies, global presence, and strong focus on innovation in precision oncology, adaptive radiotherapy, proton therapy, and AI-enabled treatment planning. Emerging Leaders such as Sumitomo, Carl Zeiss, and Hitachi are strengthening their market presence through continuous technological advancements and specialized radiotherapy offerings. Pervasive Players, including Philips and Mevion, possess established business strategies and focused technology portfolios, particularly in imaging and proton therapy applications. Meanwhile, Participants such as MIM Software, Panacea Medical Technologies, Optivus Proton Therapy, Perspective Therapeutics, and Provision Healthcare are expanding their market presence through niche product offerings, software solutions, and specialized radiotherapy applications. Although these companies currently hold smaller market shares compared to leading players, their growing focus on innovation, strategic collaborations, and expansion into emerging application areas is expected to enhance their competitiveness in the global radiotherapy market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Siemens Healthineers AG (Germany)
- Elekta (Sweden)
- Accuray Incorporated (US)
- IBA Worldwide (Belgium)
- ViewRay, Inc. (US)
- Perspective Therapeutics (US)
- Hitachi Ltd. (Japan)
- Sumitomo Heavy Industries, Ltd. (Japan)
- Carl Zeiss Meditec AG (Germany)
- MIM Software Inc. (US)
- Panacea Medical Technologies Pvt. Ltd. (India)
- Provision Healthcare (US)
- Mevion Medical Systems (US)
- Koninklijke Philips N.V. (Netherlands)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 7.58 Billion |
| Market Forecast in 2026 (Value) | USD 7.98 Billion |
| Market Forecast in 2031 (Value) | USD 10.68 Billion |
| Growth Rate | CAGR of 6.0% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: RADIOTHERAPY MARKET: GROWTH, SIZE, SHARE, AND TRENDS REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Radiotherapy System Manufacturer |
|
|
| Hospitals/Independent Radiotherapy Centers |
|
|
RECENT DEVELOPMENTS
- February 2025 : IBA Worldwide entered into an agreement with the Asian Institute of Gastroenterology (AIG) to provide a ProteusONE compact therapy system to support research in its oncology center.
- January 2025 : Accuray Incorporated (US) received NMPA approval for the Radixact SynC System and the CyberKnife S7 System, which provide accurate and minimally invasive radiotherapy.
- August 2024 : Accuray received CE Mark for the new Helical Radiation Delivery System.
- May 2024 : Elekta launched the AI-powered adaptive CT-Linac, Evo, which is capable of delivering both offline and online adaptive radiation therapy, in addition to improving standard IGRT treatments.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
- 5.1 INTRODUCTION
-
5.2 MARKET DYNAMICSDRIVERS- Advancements in Radiotherapy Treatment- Growing patient population- Increasing initiatives to promote radiotherapy awareness- Growing use of particle therapy for cancer treatmentRESTRAINTS- Lack of adequate healthcare infrastructure- High capital cost of radiotherapy- Complexity of radiotherapyOPPORTUNITIES- Emerging economies- Favorable changes in US radiotherapy payment model- Government and private investments to meet rising demand for cancer treatmentCHALLENGES- Dearth of skilled personnel- Difficulties in Visualizing Tumors During Radiotherapy- Risk of radiation exposure
-
5.3 REGULATORY ANALYSISREGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
-
5.4 REGULATORY LANDSCAPENORTH AMERICA- US- CanadaEUROPEASIA PACIFIC- China- Japan- India
- 5.5 REIMBURSEMENT SCENARIO
-
5.6 VALUE CHAIN ANALYSISRESEARCH & DEVELOPMENTPROCUREMENT & PRODUCT DEVELOPMENTMARKETING, SALES, AND DISTRIBUTION
-
5.7 SUPPLY CHAIN ANALYSISPROMINENT COMPANIESSMALL & MEDIUM-SIZED ENTERPRISESEND USERS
-
5.8 ECOSYSTEM ANALYSIS
-
5.9 PORTER’S FIVE FORCES ANALYSISINTENSITY OF COMPETITIVE RIVALRYBARGAINING POWER OF SUPPLIERSBARGAINING POWER OF BUYERSTHREAT OF SUBSTITUTESTHREAT OF NEW ENTRANTS
-
5.10 KEY STAKEHOLDERS & BUYING CRITERIAKEY STAKEHOLDERS IN BUYING PROCESSKEY BUYING CRITERIA
-
5.11 TRADE ANALYSISIMPORT DATAEXPORT DATA
- 5.12 PATENT ANALYSIS
-
5.13 PRICING ANALYSISAVERAGE SELLING PRICE, BY KEY PLAYERAVERAGE SELLING PRICE TREND, BY REGIONAVERAGE SELLING PRICE, BY COUNTRY
-
5.14 TECHNOLOGY ANALYSISKEY TECHNOLOGIES- Linear accelerators (LINACs)- Image-guided radiotherapy (IGRT)- Intensity-modulated radiotherapy (IMRT)- Particle therapy- Surface-guided radiotherapy (SGRT)COMPLEMENTARY TECHNOLOGIES- Chemotherapy- Immunotherapy- Hyperthermia therapyADJACENT TECHNOLOGIES- Medical imaging technologies- Radioisotope production technologies- Systematic radiotherapy- Theranostics
-
5.15 CASE STUDY ANALYSISCASE STUDY: ENHANCING PATIENT SAFETY—SBRT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC)CASE STUDY: RADIOTHERAPY FOR BREAST CANCER IN A PATIENT WITH HEREDITARY COPROPORPHYRIACASE STUDY: A CASE STUDY OF RADIATION THERAPY TREATMENT FOR TRANSITIONAL CELL CARCINOMA OF THE DISTAL URETHRA
- 5.16 KEY CONFERENCES & EVENTS, 2025–2026
- 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
- 5.18 INVESTMENT & FUNDING SCENARIO
- 5.19 UNMET NEEDS
- 5.20 IMPACT OF GENERATIVE AI ON RADIOTHERAPY MARKET
- 6.1 INTRODUCTION
-
6.2 SYSTEMSCONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET
-
6.3 SOFTWARE & SERVICESINCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH
- 7.1 INTRODUCTION
-
7.2 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIESLINACS- Conventional LINACs- Stereotactic advanced electron/cobalt-60 LINACs- MRI LINACsPARTICLE THERAPY- Cyclotrons- Synchrotrons- SynchrocyclotronsCONVENTIONAL COBALT-60 TELETHERAPY- Complex dose delivery planning and radiation exposure to limit market adoption
-
7.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPYSEEDS- Adverse side-effects associated with seeds to limit adoptionAFTERLOADERS- Proper positioning and better control of isotopes in modern afterloaders to drive demandIORT SYSTEMS- Rising adoption of electronic brachytherapy procedures to support growthAPPLICATORS- High risk of radiation exposure in manual applicators to limit growth
- 8.1 INTRODUCTION
-
8.2 EXTERNAL BEAM RADIOTHERAPY APPLICATIONSPROSTATE CANCER- High incidence rate and efficiency of EBRT in prostate cancer treatment to support growthBREAST CANCER- Therapeutic benefits of EBRT to drive marketLUNG CANCER- High prevalence of lung cancer and efficiency of EBRT to drive marketHEAD & NECK CANCER- Noninvasive treatment of head & neck cancers to drive marketCOLORECTAL CANCER- High incidence of colorectal cancer to support market growthOTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS
-
8.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONSPROSTATE CANCER- Precision of brachytherapy to drive marketGYNECOLOGICAL CANCER- Availability of alternatives to hinder adoption of brachytherapyBREAST CANCER- Wide usage as replacement for traditional EBRT to drive marketCERVICAL CANCER- Effectiveness of combined brachytherapy-chemotherapy procedures to support adoptionPENILE CANCER- Rising awareness and effectiveness of brachytherapy to drive marketOTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS
- 9.1 INTRODUCTION
-
9.2 EXTERNAL BEAM RADIOTHERAPYIMAGE-GUIDED RADIOTHERAPY- Growing demand in treating deep-seated tumors to drive marketINTENSITY-MODULATED RADIOTHERAPY- Advantages over 2D and 3D-CRT to boost adoption3D CONFORMAL RADIOTHERAPY- High precision and minimal damage to nearby tissues to boost adoptionSTEREOTACTIC RADIOTHERAPY- Minimally invasive procedure to drive end-user preferencePARTICLE THERAPY- High usage as primary mode of cancer treatment to sustain market growthOTHER EXTERNAL BEAM RADIOTHERAPY PROCEDURES
-
9.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPYLDR BRACHYTHERAPY- Low risk of radiation exposure to surrounding tissues to drive adoptionHDR BRACHYTHERAPY- Possibility of tissue injury to affect adoptionPDR BRACHYTHERAPY- Combination of advantages to boost growth
- 10.1 INTRODUCTION
-
10.2 HOSPITALSHOSPITALS TO DOMINATE END-USER MARKET
-
10.3 INDEPENDENT RADIOTHERAPY CENTERSLOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH
- 11.1 INTRODUCTION
-
11.2 NORTH AMERICAMACROECONOMIC OUTLOOK FOR NORTH AMERICAUS- Changes in reimbursement scenario to drive growthCANADA- Favorable initiatives from government and private organizations to boost market
-
11.3 EUROPEMACROECONOMIC OUTLOOK FOR EUROPEGERMANY- Availability of novel radiotherapy products to drive marketFRANCE- Presence of advanced healthcare system to augment growthUK- High incidence of cancer to drive marketSPAIN- Growing research activities on cancer care to promote growthITALY- Rising clinical trials and research activities in hospitals and universities to support growthREST OF EUROPE
-
11.4 ASIA PACIFICMACROECONOMIC OUTLOOK FOR ASIA PACIFICJAPAN- Rising geriatric population to encourage growthCHINA- Growing partnerships among market players to support growthINDIA- Increasing preference for minimally invasive treatment to propel marketSOUTH KOREA- Increasing incidence of cancer to support marketAUSTRALIA- Growing cancer cases to fuel marketREST OF ASIA PACIFIC
-
11.5 LATIN AMERICAMACROECONOMIC OUTLOOK FOR LATIN AMERICABRAZIL- Increasing prevalence of cancer to fuel marketMEXICO- Rising target population to boost market growthREST OF LATIN AMERICA
-
11.6 MIDDLE EAST & AFRICAMACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICAGCC COUNTRIES- Booming medical tourism to expedite growthREST OF MIDDLE EAST & AFRICA
- 12.1 INTRODUCTION
-
12.2 KEY PLAYER STRATEGY/RIGHT TO WINOVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET
- 12.3 REVENUE ANALYSIS, 2019–2023
-
12.4 MARKET SHARE ANALYSIS, 2023EXTERNAL BEAM RADIOTHERAPY MARKET RANKINGINTERNAL BEAM RADIOTHERAPY MARKET RANKING
-
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023STARSEMERGING LEADERSPERVASIVE PLAYERSPARTICIPANTSCOMPANY FOOTPRINT: KEY PLAYERS, 2023- Company footprint- Technology footprint- Application footprint- End-user footprint- Region footprint
-
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023PROGRESSIVE COMPANIESRESPONSIVE COMPANIESDYNAMIC COMPANIESSTARTING BLOCKSCOMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
-
12.7 COMPANY VALUATION & FINANCIAL METRICS
- 12.8 BRAND/PRODUCT COMPARISON
-
12.9 COMPETITIVE SCENARIOPRODUCT LAUNCHES AND APPROVALSDEALSEXPANSIONS
-
13.1 KEY PLAYERSSIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.)- Business overview- Products/Software offered- Recent developments- MnM viewELEKTA- Business overview- Products/Solutions offered- Recent developments- MnM viewACCURAY INCORPORATED- Business overview- Products/Services/Software offered- Recent developments- MnM viewIBA WORLDWIDE- Business overview- Products/Services offered- Recent developments- MnM viewVIEWRAY, INC.- Business overview- Products offered- Recent developmentsPERSPECTIVE THERAPEUTICS- Business overview- Products offered- Recent developmentsHITACHI LTD. (HITACHI HIGH-TECH CORPORATION)- Business overview- Products offered- Recent developmentsSUMITOMO HEAVY INDUSTRIES, LTD.- Business overview- Products offered- Recent developmentsCARL ZEISS MEDITEC AG (A WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG)- Business overview- Products offered- Recent developmentsMIM SOFTWARE INC.- Business overview- Software offered- Recent developmentsPANACEA MEDICAL TECHNOLOGIES PVT. LTD.- Business overview- Products/Software offered- Recent developmentsPROVISION HEALTHCARE- Business overview- Products/ offeredMEVION MEDICAL SYSTEMS- Business overview- Products offered- Recent developmentsKONINKLIJKE PHILIPS N.V.- Business overview- Software offered- Recent developments
-
13.2 OTHER PLAYERSSHINVA MEDICAL INSTRUMENT CO., LTD.BRAINLAB AGRAYSEARCH LABORATORIESOPTIVUS PROTON THERAPY, INC.BEBIG MEDICALP-CURETHERAGENICS CORPORATIONPROTOM INTERNATIONALDOS ISOFT SAISOAID, LLCMAGNETTX ONCOLOGY SOLUTIONS LTD.
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
- TABLE 1 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 2 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 3 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 4 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 5 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
- TABLE 7 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES
- TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
- TABLE 9 INDIA: MEDICAL DEVICE CLASSIFICATION UNDER CDSCO
- TABLE 10 CPT CODES FOR MAJOR RADIOTHERAPY TREATMENT MODALITIES
- TABLE 11 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
- TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY DEVICES
- TABLE 13 KEY BUYING CRITERIA FOR RADIOTHERAPY
- TABLE 14 IMPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2019−2023 (USD)
- TABLE 15 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2019−2023 (USD)
- TABLE 16 LIST OF MAJOR PATENT INNOVATIONS AND PATENT REGISTRATIONS, 2022–2025
- TABLE 17 AVERAGE SELLING PRICE OF TOP TWO PRODUCTS, BY KEY PLAYER, 2023 (USD)
- TABLE 18 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY PRODUCTS, BY REGION, 2022–2024 (USD)
- TABLE 19 RADIOTHERAPY MARKET: KEY CONFERENCES & EVENTS, 2025–2026
- TABLE 20 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS
- TABLE 21 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2022–2030 (USD MILLION)
- TABLE 22 RADIOTHERAPY SYSTEMS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 23 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 24 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 25 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 26 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 27 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 28 LINACS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 29 CONVENTIONAL LINACS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 30 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 31 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 32 CYBERKNIFE MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 33 GAMMA KNIFE MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 34 TOMOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 35 MRI LINACS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 36 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION)
- TABLE 37 PARTICLE THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 38 CYCLOTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 39 SYNCHROTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 40 SYNCHROCYCLOTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 41 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 44 SEEDS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 45 AFTERLOADERS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 46 IORT SYSTEMS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 47 APPLICATORS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 48 RADIOTHERAPY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)
- TABLE 49 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 50 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 51 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 52 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 53 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 54 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD & NECK CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 55 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 56 OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 57 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 60 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 61 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 62 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR CERVICAL CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 63 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PENILE CANCER, BY REGION, 2022–2030 (USD MILLION)
- TABLE 64 OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 65 RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)
- TABLE 66 EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 67 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 68 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 69 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 70 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 71 STEREOTACTIC RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 72 PARTICLE THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 73 OTHER EBRT PROCEDURES MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 74 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 75 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 76 LDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 77 HDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 78 PDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 79 RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)
- TABLE 80 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION)
- TABLE 81 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2022–2030 (USD MILLION)
- TABLE 82 RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 83 RADIOTHERAPY MARKET: INSTALLED BASE, 2024 (UNITS)
- TABLE 84 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
- TABLE 85 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 86 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 87 NORTH AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 88 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 89 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION)
- TABLE 90 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 91 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 92 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 93 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)
- TABLE 94 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY /BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 95 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)
- TABLE 96 NORTH AMERICA: MACROECONOMIC OUTLOOK
- TABLE 97 NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025
- TABLE 98 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 99 US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 100 US: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 101 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 102 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 103 CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 104 CANADA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 105 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 106 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
- TABLE 107 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 108 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 109 EUROPE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 110 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 111 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION)
- TABLE 112 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 113 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 114 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 115 EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)
- TABLE 116 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 117 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)
- TABLE 118 EUROPE: MACROECONOMIC OUTLOOK
- TABLE 119 EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025
- TABLE 120 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 121 GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 122 GERMANY: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 123 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 124 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 125 FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 126 FRANCE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 127 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 128 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 129 UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 130 UK: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 131 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 132 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 133 SPAIN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 134 SPAIN: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 135 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 136 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 137 ITALY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 138 ITALY: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 139 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 140 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 141 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 142 REST OF EUROPE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 143 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 144 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
- TABLE 145 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 146 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 147 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 148 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 149 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION)
- TABLE 150 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 151 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 152 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 153 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)
- TABLE 154 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 155 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)
- TABLE 156 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- TABLE 157 ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025
- TABLE 158 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 159 JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 160 JAPAN: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 161 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 162 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 163 CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 164 CHINA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 165 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 166 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 167 INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 168 INDIA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 169 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 170 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 171 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 172 SOUTH KOREA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 173 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 174 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 175 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 176 AUSTRALIA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 177 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 178 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 179 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 180 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 181 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 182 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
- TABLE 183 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 184 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 185 LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 186 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 187 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION)
- TABLE 188 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 189 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 190 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 191 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)
- TABLE 192 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 193 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)
- TABLE 194 LATIN AMERICA: MACROECONOMIC OUTLOOK
- TABLE 195 LATIN AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025
- TABLE 196 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 197 BRAZIL: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 198 BRAZIL: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 199 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 200 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 201 MEXICO: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 202 MEXICO: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 203 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 204 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 205 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 206 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 207 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 208 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)
- TABLE 209 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 210 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 211 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 212 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 213 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 214 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 215 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 216 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 217 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)
- TABLE 218 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 219 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)
- TABLE 220 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
- TABLE 221 MIDDLE EAST & AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025
- TABLE 222 GCC COUNTRIES: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 223 GCC COUNTRIES: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 224 GCC COUNTRIES: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 225 GCC COUNTRIES: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 226 REST OF MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
- TABLE 227 REST OF MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 228 REST OF MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 229 REST OF MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)
- TABLE 230 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOTHERAPY MARKET
- TABLE 231 RADIOTHERAPY MARKET: DEGREE OF COMPETITION
- TABLE 232 RADIOTHERAPY MARKET: TECHNOLOGY FOOTPRINT
- TABLE 233 RADIOTHERAPY MARKET: APPLICATION FOOTPRINT
- TABLE 234 RADIOTHERAPY MARKET: END-USER FOOTPRINT
- TABLE 235 RADIOTHERAPY MARKET: REGION FOOTPRINT
- TABLE 236 RADIOTHERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
- TABLE 237 RADIOTHERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
- TABLE 238 RADIOTHERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–JANUARY 2025
- TABLE 239 RADIOTHERAPY MARKET: DEALS, JANUARY 2021–JANUARY 2025
- TABLE 240 RADIOTHERAPY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024
- TABLE 241 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): COMPANY OVERVIEW
- TABLE 242 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): PRODUCTS/SOFTWARE OFFERED
- TABLE 243 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): PRODUCT APPROVALS, JANUARY 2021–OCTOBER 2024
- TABLE 244 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): DEALS, JANUARY 2021− OCTOBER 2024
- TABLE 245 ELEKTA: COMPANY OVERVIEW
- TABLE 246 ELEKTA: PRODUCTS/SOLUTIONS OFFERED
- TABLE 247 ELEKTA: PRODUCTS LAUNCHES AND APPROVALS, JANUARY 2021−JANUARY 2025
- TABLE 248 ELEKTA: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 249 ELEKTA: EXPANSIONS, JANUARY 2021− OCTOBER 2024
- TABLE 250 ACCURAY INCORPORATED: COMPANY OVERVIEW
- TABLE 251 ACCURAY INCORPORATED: PRODUCTS/SERVICES/SOFTWARE OFFERED
- TABLE 252 ACCURAY INCORPORATED: PRODUCT APPROVALS, JANUARY 2021−JANUARY 2025
- TABLE 253 ACCURAY INCORPORATED: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 254 ACCURAY INCORPORATED: EXPANSIONS, JANUARY 2021− OCTOBER 2024
- TABLE 255 IBA WORLDWIDE: COMPANY OVERVIEW
- TABLE 256 IBA WORLDWIDE: PRODUCTS/SERVICES OFFERED
- TABLE 257 IBA WORLDWIDE: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
- TABLE 258 IBA WORLDWIDE: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 259 VIEWRAY, INC.: COMPANY OVERVIEW
- TABLE 260 VIEWRAY, INC.: PRODUCTS OFFERED
- TABLE 261 VIEWRAY, INC.: PRODUCT APPROVALS, JANUARY 2021−JANUARY 2025
- TABLE 262 VIEWRAY, INC.: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 263 PERSPECTIVE THERAPEUTICS: COMPANY OVERVIEW
- TABLE 264 PERSPECTIVE THERAPEUTICS: PRODUCTS OFFERED
- TABLE 265 PERSPECTIVE THERAPEUTICS: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 266 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): COMPANY OVERVIEW
- TABLE 267 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): PRODUCTS OFFERED
- TABLE 268 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): DEALS, JANUARY 2021− OCTOBER 2024
- TABLE 269 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY OVERVIEW
- TABLE 270 SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCTS OFFERED
- TABLE 271 SUMITOMO HEAVY INDUSTRIES LTD.: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
- TABLE 272 SUMITOMO HEAVY INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
- TABLE 273 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): COMPANY OVERVIEW
- TABLE 274 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): PRODUCTS OFFERED
- TABLE 275 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
- TABLE 276 MIM SOFTWARE INC.: COMPANY OVERVIEW
- TABLE 277 MIM SOFTWARE INC.: SOFTWARE OFFERED
- TABLE 278 MIM SOFTWARE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−JANUARY 2025
- TABLE 279 MIM SOFTWARE INC.: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 280 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
- TABLE 281 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCTS/SOFTWARE OFFERED
- TABLE 282 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−JANUARY 2025
- TABLE 283 PROVISION HEALTHCARE: COMPANY OVERVIEW
- TABLE 284 PROVISION HEALTHCARE: PRODUCTS OFFERED
- TABLE 285 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW
- TABLE 286 MEVION MEDICAL SYSTEMS: PRODUCTS OFFERED
- TABLE 287 MEVION MEDICAL SYSTEMS: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
- TABLE 288 MEVION MEDICAL SYSTEMS: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 289 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
- TABLE 290 KONINKLIJKE PHILIPS N.V.: SOFTWARE OFFERED
- TABLE 291 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
- TABLE 292 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−JANUARY 2025
- TABLE 293 SHINVA MEDICAL INSTRUMENT CO., LTD.: COMPANY OVERVIEW
- TABLE 294 BRAINLAB AG: COMPANY OVERVIEW
- TABLE 295 RAYSEARCH LABORATORIES: COMPANY OVERVIEW
- TABLE 296 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW
- TABLE 297 OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW
- TABLE 298 BEBIG MEDICAL: COMPANY OVERVIEW
- TABLE 299 P-CURE: COMPANY OVERVIEW
- TABLE 300 THERAGENICS CORPORATION: COMPANY OVERVIEW
- TABLE 301 PROTOM INTERNATIONAL: COMPANY OVERVIEW
- TABLE 302 DOSISOFT SA: COMPANY OVERVIEW
- TABLE 303 ISOAID, LLC: COMPANY OVERVIEW
- TABLE 304 MAGNETTX ONCOLOGY SOLUTIONS LTD.: COMPANY OVERVIEW
- FIGURE 1 RESEARCH DESIGN
- FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
- FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
- FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)
- FIGURE 5 RADIOTHERAPY MARKET: MARKET SIZE ESTIMATION METHODOLOGY
- FIGURE 6 DATA TRIANGULATION METHODOLOGY
- FIGURE 7 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024 VS. 2030 (USD MILLION)
- FIGURE 8 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION)
- FIGURE 9 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION)
- FIGURE 10 RADIOTHERAPY MARKET SHARE, BY END USER, 2024 VS. 2030(%)
- FIGURE 11 RADIOTHERAPY MARKET: REGIONAL SNAPSHOT
- FIGURE 12 RISING CANCER PREVALENCE WORLDWIDE TO DRIVE MARKET GROWTH
- FIGURE 13 INTENSITY-MODULATED RADIATION THERAPY TO HOLD LARGEST SHARE OF MARKET IN 2024
- FIGURE 14 LINACS HELD LARGEST SHARE OF EUROPEAN MARKET IN 2O23
- FIGURE 15 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
- FIGURE 16 NORTH AMERICA WILL CONTINUE TO DOMINATE RADIOTHERAPY MARKET DURING FORECAST PERIOD
- FIGURE 17 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 18 PROJECTED INCREASE IN CANCER CASES, 2020 VS. 2040
- FIGURE 19 RADIOTHERAPY MARKET: VALUE CHAIN ANALYSIS
- FIGURE 20 RADIOTHERAPY MARKET: SUPPLY CHAIN ANALYSIS
- FIGURE 21 RADIOTHERAPY MARKET: ECOSYSTEM ANALYSIS
- FIGURE 22 RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS
- FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY
- FIGURE 24 KEY BUYING CRITERIA FOR RADIOTHERAPY
- FIGURE 25 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2019–2023 (USD THOUSAND)
- FIGURE 26 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2019−2023 (USD THOUSAND)
- FIGURE 27 RADIOTHERAPY MARKET: PATENTS APPLIED AND GRANTED, 2014–2025
- FIGURE 28 AVERAGE SELLING PRICE, BY KEY PLAYER, 2023 (USD)
- FIGURE 29 AVERAGE SELLING PRICE OF RADIOTHERAPY PRODUCTS, BY COUNTRY, 2024 (USD)
- FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
- FIGURE 31 RADIOTHERAPY MARKET: NUMBER OF DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION)
- FIGURE 32 RADIOTHERAPY MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION)
- FIGURE 33 VALUE OF INVESTOR DEALS IN RADIOTHERAPY MARKET, BY KEY PLAYER, 2019–2023 (USD MILLION)
- FIGURE 34 USE OF GEN AI IN RADIOTHERAPY MARKET
- FIGURE 35 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT
- FIGURE 36 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT
- FIGURE 37 REVENUE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET (2019−2023)
- FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET (2023)
- FIGURE 39 EXTERNAL BEAM RADIOTHERAPY MARKET RANKING, BY KEY PLAYER, 2023
- FIGURE 40 INTERNAL BEAM RADIOTHERAPY MARKET RANKING, BY KEY PLAYER, 2023
- FIGURE 41 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
- FIGURE 42 RADIOTHERAPY MARKET: COMPANY FOOTPRINT
- FIGURE 43 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
- FIGURE 44 EV/EBITDA OF KEY VENDORS
- FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 46 RADIOTHERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
- FIGURE 47 SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): COMPANY SNAPSHOT 2024
- FIGURE 48 ELEKTA: COMPANY SNAPSHOT 2023
- FIGURE 49 ACCURAY INCORPORATED: COMPANY SNAPSHOT 2024
- FIGURE 50 IBA WORLDWIDE: COMPANY SNAPSHOT 2023
- FIGURE 51 VIEWRAY, INC.: COMPANY SNAPSHOT 2022
- FIGURE 52 PERSPECTIVE THERAPEUTICS: COMPANY SNAPSHOT 2023
- FIGURE 53 HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): COMPANY SNAPSHOT 2023
- FIGURE 54 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT 2023
- FIGURE 55 CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): COMPANY SNAPSHOT 2023
- FIGURE 56 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT 2023
Methodology
This study involved the extensive use of both primary and secondary sources. Exhaustive secondary research was done to collect information on the radiotherapy industry. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market sizes of the radiotherapy market's segments and subsegments. The research process involved examining various factors affecting the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and key players' strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies House documents, investor presentations, and SEC filings. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the radiotherapy market. It was also used to obtain important information about key players, market classification & segmentation according to industry trends, down to the bottom-most level, and key developments from market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
The market for companies offering radiotherapy products is derived from secondary data available through paid and unpaid sources, by analyzing the product portfolios of the major companies in the ecosystem and rating them by performance and quality. Various sources were consulted during the secondary research process to identify and collect information for this study. Secondary research was used to obtain critical information on the industry's value chain, the total pool of key players, market classification, and segmentation from market- and technology-oriented perspectives.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the radiotherapy market. The primary sources from the demand side include OEMs, private and contract testing organizations, and service providers, among others. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
After the complete market engineering (calculations for market statistics, market breakdown, market estimation, market forecasting and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at fill primary research was also conducted to identify the segmentation types industry trends competitive landscape of radiotherapy offered by various market players and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends and key players strategies.
In the complete market engineering process, the top-down and bottom-up approaches were extensively used, along with several data regulation methods, to perform market estimation and forecasting across the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analyses were conducted across the entire market engineering process to identify key insights throughout the report.
A breakdown of the primary respondents is provided below:
Note 1: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2025, Tier 1 = >USD 2 billion, Tier 2 = USD 50 million to USD 2 billion, and Tier 3 = <USD 50 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the radiotherapy market. These methods were also used extensively to estimate the size of various market segments.
To determine the size of the global radiotherapy market, revenue share analysis was employed with the leading players. In this case, key market players have been identified, and their radiotherapy product business revenues have been determined using insights gathered during the primary and secondary research phases. Secondary research included the study of top market players' annual and financial reports. On the other hand, primary research included in-depth interviews with key opinion leaders, particularly chief executive officers, directors, and key marketing executives.
Radiotherapy Market : Top-Down and Bottom-Up Approach

Data Triangulation
After arriving at the overall market size through the market size estimation process described above, the global radiotherapy market was segmented. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the radiotherapy market was validated using both top-down and bottom-up approaches.
Market Definition
The radiotherapy market includes a range of products, solutions, technologies, and services that utilize high-energy radiation for therapeutic purposes. This encompasses various types of radiation, such as X-ray, gamma, electron, and particle radiation. The technologies segment of radiotherapy features systems designed to treat diseases, primarily cancer. This includes external beam radiotherapy methods like LINAC, MRI-LINAC, and cobalt-60 teletherapy. Additionally, internal radiotherapy solutions, commonly known as brachytherapy, are also part of this market segment. Other components of the radiotherapy market include software for imaging and treatment planning. Furthermore, the market provides maintenance and training services related to radiotherapy technologies.
Key Stakeholders
- Radiotherapy product manufacturing companies
- Distributors, suppliers, and commercial service providers
- Healthcare service providers
- Clinical research organizations (CROs)
- Radiotherapy service providers
- Radiotherapy product distributors
- Medical research laboratories
- Cancer care centers
- Cancer research organizations
- Academic medical centers and universities
- Market research and consulting firms
Report Objectives
- To define, describe, and forecast the radiotherapy market based on offering, technology, application, procedure, end user, and region
- To provide detailed information regarding the major factors influencing the growth potential of the global radiotherapy market (drivers, restraints, opportunities, challenges, and trends)
- To analyze the micromarkets for individual growth trends, prospects, and contributions to the global radiotherapy market
- To analyze key growth opportunities in the global radiotherapy market for key stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments and/or subsegments with respect to five major regions: North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and the Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America), and the Middle East & Africa (GCC Countries and the Rest of Middle East & Arica)
- To profile the key players in the global radiotherapy market and comprehensively analyze their market shares and core competencies
- To track and analyze the competitive developments undertaken in the global radiotherapy market, such as agreements, expansions, and product launches
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global radiotherapy market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top 16 companies
Company Information
- Detailed analysis and profiling of additional market players (up to 15)
Geographic Analysis
- Further breakdown of the Rest of Europe radiotherapy market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
- Further breakdown of the Rest of Asia Pacific radiotherapy market into Singapore, Taiwan, New Zealand, the Philippines, Malaysia, and other APAC countries
- Further breakdown of the Rest of Latin America radiotherapy market into Argentina, Chile, Peru, and Colombia, among others
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Radiotherapy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
Growth opportunities and latent adjacency in Radiotherapy Market